Bendamustine

Strategic Sequencing of T-Cell Therapies in Relapsed/Refractory Multiple Myeloma: Expert Guidelines

12 days ago

• CAR T therapy is recommended before bispecific antibodies in RRMM due to its potential for durable and deep responses, according to IMWG and ASCO guidelines. • Bridging therapy selection should be based on disease tempo and prior treatments, with GPRC5D-targeted bispecifics preferred when bridging to BCMA-directed CAR T to avoid antigen overlap. • Treatment decisions for RRMM patients should consider disease progression rate, with rapid progression favoring readily available bispecific antibodies and slower progression allowing time for CAR T manufacturing.

Eagle Pharmaceuticals Secures $69 Million Deal to Monetize BENDEKA Royalties

2 months ago

• Eagle Pharmaceuticals has entered into a $69 million royalty purchase agreement with Blue Owl Capital to sell its royalty interest in BENDEKA, a treatment for chronic lymphocytic leukemia and non-Hodgkin lymphoma. • The non-dilutive capital will be used to repay $52.5 million in existing debt, with remaining proceeds allocated to general corporate purposes and ongoing R&D programs. • Eagle continues to invest in its pipeline, including CAL02 for severe community-acquired bacterial pneumonia and EA 114, a novel formulation of Fulvestrant for hormone-receptor-positive metastatic breast cancer.

Gazyva Shows Significant Improvement in Lupus Nephritis Treatment: Phase III REGENCY Trial Results

3 months ago

• Genentech's Phase III REGENCY trial demonstrates that Gazyva plus standard therapy achieved 46.4% complete renal response in lupus nephritis patients compared to 33.1% with standard therapy alone. • The study, published in NEJM, showed clinically meaningful improvements in complement levels and reductions in anti-dsDNA markers, indicating reduced disease activity and inflammation. • Results were consistent across all patient subgroups, including those with Class IV lupus nephritis and higher baseline proteinuria levels, while maintaining Gazyva's established safety profile.

Third-Generation CAR T-Cell Therapy Shows Promise in Relapsed/Refractory CLL

5 months ago

• A phase 1/2 study of HD-CAR-1, a third-generation CAR T-cell therapy, demonstrates encouraging response rates in heavily pretreated CLL patients. • Six of nine patients (67%) achieved complete remission (CR) three months post-treatment, with 83% showing undetectable minimal residual disease. • With a median follow-up of 27 months, the progression-free survival rate was 30%, and achieving CR correlated with significantly longer PFS (P = .024). • The therapy showed a favorable safety profile, with only one case of grade 3 cytokine release syndrome and no neurotoxicity observed.

Yescarta Demonstrates Durable Response and Long-Term Survival in NHL Patients After Five Years

5 months ago

• A five-year follow-up of the ZUMA-5 trial shows Yescarta maintains durable responses in relapsed/refractory non-Hodgkin lymphoma (NHL) patients, including follicular lymphoma (FL) and marginal zone lymphoma (MZL). • The study reported a median progression-free survival of 62.2 months and a median duration of response of 60.4 months, indicating a potential curative effect for these difficult-to-treat blood cancers. • Over half of the patients were alive at the time of analysis, with many requiring no subsequent therapy, suggesting Yescarta may offer a chance for longer survival without additional treatments. • No new Yescarta-related safety signals emerged during the five-year analysis, reinforcing its manageable long-term safety profile in patients with relapsed or refractory NHL.

Genentech's Gazyva Shows Positive Phase III Results in Lupus Nephritis Treatment

8 months ago

• Genentech's Gazyva met its primary endpoint in a Phase III REGENCY study, demonstrating statistically significant benefits for lupus nephritis patients. • Patients treated with Gazyva plus standard therapy achieved a higher rate of complete renal response at 76 weeks compared to standard therapy alone. • The study also showed statistically significant improvements in secondary endpoints, including reduced corticosteroid use and improved proteinuric response. • Gazyva targets disease-causing B cells, potentially preventing or delaying progression to end-stage kidney disease in lupus nephritis patients.

FDA Approves PEMFEXY® Combination Therapy for Metastatic Non-Small Cell Lung Cancer

2 years ago

• Eagle Pharmaceuticals' PEMFEXY® gains FDA approval for use with pembrolizumab and platinum chemotherapy in metastatic non-squamous NSCLC patients without EGFR or ALK aberrations. • PEMFEXY®, a ready-to-dilute liquid formulation, now holds the same indications as ALIMTA®, offering advantages like eliminating reconstitution steps. • This marks the fifth indication for PEMFEXY®, expanding its role in treating non-squamous NSCLC and mesothelioma, enhancing Eagle's oncology portfolio. • The approval strengthens Eagle Pharmaceuticals' position in the market, providing a valuable treatment option for patients undergoing chemotherapy.